The ADDF/Belfer ApoE Therapeutics Innovation Program

Request for Proposals (RFP)

**SUMMARY:** The Alzheimer’s Drug Discovery Foundation (ADDF) and the Robert A. and Renée E. Belfer Family Foundation established The ADDF/Belfer ApoE Therapeutics Innovation Program to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms. Although only ~20% of humans are APOE ε4 carriers, these individuals account for up to 65% of all Alzheimer’s disease cases. Therapies that target apoE are critically needed now. Recent scientific advances have made this a possibility.

This program will allow the ADDF to substantially build on its strategic investment in apoE drug discovery and development and will support both preclinical and clinical stage programs.

**MECHANISM(S) OF SUPPORT:** Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program related investment. The ADDF will provide 1 or 2 years funding for up to $300,000 per application for pre-clinical programs, and up to $1,000,000 per application for clinical trials of novel agents such as phase 1b or 2a studies employing biomarkers as outcome measures. All applications must be submitted electronically at www.alzdiscovery.org.

**2015 QUARTERLY DEADLINES**
- March 10
- June 16
- September 22
- December 10

*Letter of Intent is due at least two weeks prior to deadline

For program-related inquiries, please contact:
Lauren Friedman, PhD, Assistant Director for Scientific Affairs
Phone: 212-901-8017 | E-mail: lfriedman@alzdiscovery.org

For application submission inquiries, please contact:
Hanna Bridges-Curry, Grants Associate
Phone: 212-901-8019 | E-mail: hbridgescurry@alzdiscovery.org